This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Office of Cancer Clinical Proteomics Research | |
|---|---|
| Name | Office of Cancer Clinical Proteomics Research |
| Formation | 2011 |
| Headquarters | Frederick, Maryland |
| Parent organization | National Cancer Institute |
Office of Cancer Clinical Proteomics Research The Office of Cancer Clinical Proteomics Research supports translational proteomics for cancer by coordinating programs, data resources, and partnerships among biomedical institutions. It operates within the National Cancer Institute and collaborates with agencies, research centers, and industry consortia to advance clinical proteogenomics, biomarker validation, and therapeutic targeting. The office funds studies, curates datasets, and integrates efforts across clinical trials, academic centers, and regulatory frameworks.
Established to accelerate proteomic characterization of cancer, the office grew from initiatives linked to the Precision Medicine Initiative, the Cancer Moonshot, and the Human Genome Project era. Its mission emphasizes reproducible proteomic assays, standardized workflows, and public data sharing aligned with policies from the National Institutes of Health, the Food and Drug Administration, and the National Academy of Sciences. Early programs were influenced by collaborations with The Cancer Genome Atlas, the Clinical Proteomic Tumor Analysis Consortium, and international projects such as the Human Proteome Project, reflecting priorities set by advisory bodies like the President's Council of Advisors on Science and Technology and funders including the Koch Institute for Integrative Cancer Research.
The office is administratively situated within the National Cancer Institute leadership structure and reports to program directors who coordinate with division chiefs at the National Institutes of Health. Leadership includes program officers, scientific directors, and advisory panels comprising investigators from institutions such as Johns Hopkins University, Harvard University, Stanford University, Massachusetts Institute of Technology, and University of California, San Francisco. External advisors have included representatives from the Broad Institute, the Fred Hutchinson Cancer Research Center, the Dana-Farber Cancer Institute, and regulatory liaisons from the Food and Drug Administration and the Centers for Medicare & Medicaid Services.
Programs prioritize proteogenomic characterization, biomarker discovery, and clinical assay development, aligned with cohorts from consortia like The Cancer Genome Atlas, the Clinical Proteomic Tumor Analysis Consortium, and cancer centers including Memorial Sloan Kettering Cancer Center and Mayo Clinic. Initiatives have supported cancer types studied at Dana-Farber Cancer Institute, University of Texas MD Anderson Cancer Center, and Cleveland Clinic and have coordinated trials associated with National Clinical Trials Network sites and cooperative groups such as SWOG and Alliance for Clinical Trials in Oncology. The office funds projects that integrate mass spectrometry workflows developed by teams at Thermo Fisher Scientific, Agilent Technologies, and academic cores at Cold Spring Harbor Laboratory and Salk Institute.
Key technologies promoted include mass spectrometry platforms from Thermo Fisher Scientific, targeted proteomics methods like selected reaction monitoring developed in laboratories at Johns Hopkins University and Stanford University, and software resources originating from the Broad Institute, European Bioinformatics Institute, and National Center for Biotechnology Information. Data resources and portals link to repositories such as the ProteomeXchange Consortium, the PRIDE Archive, and the Cancer Data Ecosystem, while analytic toolchains leverage packages from Bioconductor, the Global Alliance for Genomics and Health, and computational infrastructures at Argonne National Laboratory and Oak Ridge National Laboratory.
The office coordinates partnerships with academic centers including Yale University, Columbia University, University of Chicago, and University of Pennsylvania; government entities such as the National Institutes of Health institutes and centers, Department of Defense research programs, and the Veterans Affairs research networks; and industry partners including Pfizer, Novartis, Roche, and technology firms like Illumina. International collaborations involve organizations such as the European Molecular Biology Laboratory, the Wellcome Trust, and the Cancer Research UK network. It also engages patient advocacy groups like the American Cancer Society and philanthropic funders such as the Bill & Melinda Gates Foundation.
The office has enabled high-impact proteogenomic atlases produced in collaboration with The Cancer Genome Atlas and the Clinical Proteomic Tumor Analysis Consortium, contributing to discoveries reported by investigators from Broad Institute, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute. Achievements include standardized proteomic assay pipelines adopted by cores at Johns Hopkins University and Stanford University, large-scale datasets deposited in ProteomeXchange Consortium and PRIDE Archive, and translational findings informing trials at MD Anderson Cancer Center and Mayo Clinic. Its work has influenced regulatory science discussions at the Food and Drug Administration and reimbursement dialogues involving the Centers for Medicare & Medicaid Services, and has been cited in guidance from the National Academy of Medicine and the Institute of Medicine.